BioCentury
ARTICLE | Finance

Dilution, then solution

Why Illumina is willing to incur dilution with pan-cancer test newco Grail

January 18, 2016 8:00 AM UTC

Illumina Inc. (NASDAQ:ILMN) thinks early cancer screening is a massive and untapped market for its DNA sequencing capabilities and is willing to incur about four years of dilution to find out whether it is right.

Last week, the company formed Grail Bio, a majority-owned subsidiary that aims to have a pan-cancer screening test for asymptomatic patients available in 2019...